Tags

Type your tag names separated by a space and hit enter

Role of Hematopoietic Cell Transplantation in Relapsed Acute Promyelocytic Leukemia.
Clin Transplant. 2020 Jun 11 [Online ahead of print]CT

Abstract

The use of all trans-retinoic acid and arsenic trioxide combination as the induction regimen for acute promyelocytic leukemia (APL) has revolutionized the management and outcomes of this disease. Modern risk adapted frontline therapy has provided excellent therapeutic results. However, significant numbers of APL patients relapse after frontline therapy, and the optimal management strategy for relapsed APL, specifically the role and type of hematopoietic cell transplantation (HCT) are still to be defined. Both autologous and allogeneic HCTs are associated with durable remission and prolonged survival when utilized in appropriate disease settings. Once remission has been achieved, consolidation with autologous HCT for APL patients with negative minimal residual disease (MRD) status, and with allogeneic HCT for APL patients with positive MRD status appear to offer the best long-term outcomes. In this article, we provide a comprehensive review of existing literature on the efficacy of HCT in treatment of relapse/refractory APL and we discuss the appropriate use of this modality.

Authors+Show Affiliations

Department of Blood & Marrow Transplant and Cellular Immunotherapy (BMT CI), Moffitt Cancer Center, Tampa, Florida, USA.Department of Blood & Marrow Transplant and Cellular Immunotherapy (BMT CI), Moffitt Cancer Center, Tampa, Florida, USA.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

32526047

Citation

Hashmi, Hamza, and Taiga Nishihori. "Role of Hematopoietic Cell Transplantation in Relapsed Acute Promyelocytic Leukemia." Clinical Transplantation, 2020, pp. e14009.
Hashmi H, Nishihori T. Role of Hematopoietic Cell Transplantation in Relapsed Acute Promyelocytic Leukemia. Clin Transplant. 2020.
Hashmi, H., & Nishihori, T. (2020). Role of Hematopoietic Cell Transplantation in Relapsed Acute Promyelocytic Leukemia. Clinical Transplantation, e14009. https://doi.org/10.1111/ctr.14009
Hashmi H, Nishihori T. Role of Hematopoietic Cell Transplantation in Relapsed Acute Promyelocytic Leukemia. Clin Transplant. 2020 Jun 11;e14009. PubMed PMID: 32526047.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Role of Hematopoietic Cell Transplantation in Relapsed Acute Promyelocytic Leukemia. AU - Hashmi,Hamza, AU - Nishihori,Taiga, Y1 - 2020/06/11/ PY - 2020/6/12/entrez PY - 2020/6/12/pubmed PY - 2020/6/12/medline KW - Acute promyelocytic leukemia KW - adults KW - hematopoietic cell transplantation KW - relapse SP - e14009 EP - e14009 JF - Clinical transplantation JO - Clin Transplant N2 - The use of all trans-retinoic acid and arsenic trioxide combination as the induction regimen for acute promyelocytic leukemia (APL) has revolutionized the management and outcomes of this disease. Modern risk adapted frontline therapy has provided excellent therapeutic results. However, significant numbers of APL patients relapse after frontline therapy, and the optimal management strategy for relapsed APL, specifically the role and type of hematopoietic cell transplantation (HCT) are still to be defined. Both autologous and allogeneic HCTs are associated with durable remission and prolonged survival when utilized in appropriate disease settings. Once remission has been achieved, consolidation with autologous HCT for APL patients with negative minimal residual disease (MRD) status, and with allogeneic HCT for APL patients with positive MRD status appear to offer the best long-term outcomes. In this article, we provide a comprehensive review of existing literature on the efficacy of HCT in treatment of relapse/refractory APL and we discuss the appropriate use of this modality. SN - 1399-0012 UR - https://www.unboundmedicine.com/medline/citation/32526047/Role_of_Hematopoietic_Cell_Transplantation_in_Relapsed_Acute_Promyelocytic_Leukemia L2 - https://doi.org/10.1111/ctr.14009 DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.